Correlation between HIF-1α, PD-L1 and lymphatic metastasis in non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-6902.2020.02.023

Abstract

Abstract:

Objective

To investigate the correlation between the expression levels of HIF-1α and PD-L1 and the risk of lymphatic metastasis in patients with non-small cell lung cancer (NSCLC).

Methods

A total of 97 NSCLC patients who underwent surgical treatment in our hospital from December 2015 to December 2017 without lymph node metastasis were selected. Immunohistochemical analysis was used to detect the expression of HIF-1α and PD-L1 in cancer lesions of all patients. Then a follow-up period of 24 months was performed to record the occurrence of lymphatic metastases. All patients were grouped according to the expression levels of HIF-1α and PD-L1, and the differences in the risk of lymphatic metastasis in patients with different expression levels of the two proteins during the follow-up period were analyzed. COX regression analysis was used to determine the relationship between HIF-1α and PD-L1 and NSCLC lymph node metastasis.

Results

All patients were followed up for an average of 19 (12, 24) months. A total of 92 patients completed the follow-up. 36 cases of lymph node metastasis occurred. The rate of lymph node metastasis was 39.13%. Lymph node metastasis rates in patients with high and low expression of HIF-1α were 92.6% and 26.9%, respectively. Lymph node metastasis rates in patients with high expression of HIF-1α were significantly higher than those in patients with low expression (log-rankχ²=63.052; P<0.001) . The incidence of lymph node metastasis in patients with high PD-L1 expression and low expression was 82.1% and 21.3%, respectively. The lymph node metastasis rate in patients with high PD-L1 expression was significantly higher than that in patients with low expression (log-rankχ²=39.555; P<0.001). HIF-1α high expression (HR=25.790, 95%CI=10.005-30.287), PD-L1 high expression (HR=16.693, 95%CI=12.014-20.356), CEA (HR=1.058, 95%CI=1.013-1.106) is a risk factor for lymphatic metastasis in patients with NSCLC (P<0.05).

Conclusion

The high expression of HIF-1α and PD-L1 has significant correlation with the risk of lymphatic metastasis in patients with NSCLC, and can be used as targets for early prediction and treatment.

Key words: HIF-1α, PD-L1, Non-small cell lung cancer, Lymph node metastasis

qian Qi, Chunmei Wang, Juan Yang, Ying Tian, Chao Feng. Correlation between HIF-1α, PD-L1 and lymphatic metastasis in non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(02): 242-246.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.02.023

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I02/242

Figures/Tables 4

References 30

1	Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
2	Antonia S, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage Ⅲ Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929.
3	Guo X, Shi J, Wen Y, et al. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer[J]. Cancer Biomark, 2018, 21(3): 547-555.
4	王　娟，齐丽萍，李晓婷，等. 周围型非小细胞肺癌纵隔淋巴结转移影响因素及临床意义[J]. 中国医学影像技术，2019, 35(10): 1490-1494.
5	Aguiar P, Mello R, Hall P, et al. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: Updated survival data[J]. Immunotherapy, 2017, 9(6): 499-506.
6	Wang S, Yan Y, Cheng Z, et al. Sotetsuflavone suppresses invasion and metastasis in non-small-cell lung cancer A549 cells by reversing EMT via the TNF-α/NF-κB and PI3K/AKT signaling pathway[J]. Cell Death Discov, 2018, 4(1): 26.
7	Li J, Wang L, Chen X, et al. CD39/CD73 up-regulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer[J]. Oncoimmunology, 2017, 6(6): e1320011.
8	Castello A, Grizzi F, Toschi L, et al.Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer[J]. Nucl Med Commun, 2018, 39(7): 636-644.
9	国家卫生和计划生育委员会，中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志，2015, 37(1): 67-78.
10	张正荣. 食管鳞癌术后复发进展模式与Tiam1表达水平相关性分析[D]. 扬州大学，2017: 8-13.
11	Portelli MA, Moseley C, Stewart CE, et al. Airway and peripheral urokinase plasminogen activator receptor is elevated in asthma, and identifies a severe, nonatopic subset of patients[J]. Allergy, 2017, 72(3): 473-482.
12	Silva WFD, Manuel J, Simões, et al. Special dyeing, histochemistry, immunohistochemistry and ultrastructure: A study of mast cells/eosinophilic granules cells (MCs/EGC) from Centropomus parallelus intestine[J]. Fish Shellfish Immunol, 2017, 60(1): 502-508.
13	Li N, Gao WJ, Liu NS. LncRNA BCAR4 promotes proliferation, invasion and metastasis of non-small cell lung cancer cells by affecting epithelial-mesenchymal transition[J]. Eur Rev Med Pharmacol Sci, 2017, 21(9): 2075-2086.
14	Guerrera F, Renaud S, Tabbó F, et al. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.[J]. Eur J Cardiothorac Surg, 2017, 51(4): 680-688.
15	Zhou Y, Gao S, Huang Y, et al. A Pilot Study of18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer：[J]. Sci Rep, 2017, 7(1): 2877.
16	Huang CW, Hsieh WC, Hsu ST, et al. The Use of PET Imaging for Prognostic Integrin α 2 β 1 Phenotyping to Detect Non-Small Cell Lung Cancer and Monitor Drug Resistance Responses[J]. Theranostics, 2017, 7(16): 4013-4028.
17	Du H, Chen Y, Hou X, et al. PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC[J]. Cell Death Dis, 2017, 8(10): e3143.
18	林冬梅. 中国非小细胞肺癌PD-L1检测现状[J]. 中华病理学杂志，2017, 46(10): 665-668.
19	Patsoukis N, Brown J, Petkova V, et al. Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation[J]. Sci Signal, 2012, 5(230): ra46
20	Munari E, Zamboni G, Marconi M, et al. PD-L1 expression heterogeneity in non-small cell lung cancer: Evaluation of small biopsies reliability[J]. Oncotarget, 2017, 8(52): 90123-90131.
21	Zhao Y, Wang X, Wu W, et al. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells[J]. Biochem Biophys Res Commun, 2019, 517(2): 201-209.
22	Samulitis B, Landowski T, Dorr R. Inhibition of protein synthesis by imexon reduces HIF-1α expression in normoxic and hypoxic pancreatic cancer cells[J]. Invest New Drugs, 2009, 27(1): 89-98.
23	孙思博，金时代，郭人花，等. STAT3在非小细胞肺癌耐药中的研究进展[J]. 中国肺癌杂志，2019, 22(7): 457-463.
24	Best S, Souza D, Kersbergen A, et al. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment[J]. Cell Metabolism, 2018, 27(4): 935.
25	Song M, Ping Y, Zhang K, et al. Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer[J]. Cancer research, 2019, 79(14): 3737.
26	薛倩倩，姚稚明，陈聪霞，等. 非小细胞肺癌肺门-叶间与纵隔淋巴结转移FDG PET SUVmax诊断阈值间的对比分析[J]. 中华核医学与分子影像杂志，2017, 37(5): 279-283.
27	王　超，刘　侠，董　迪，等. 基于影像组学的非小细胞肺癌淋巴结转移预测[J]. 自动化学报，2019, 45(6): 1087-1093.
28	Tomita M, Matsuzaki Y, Edagawa M, et al. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma[J]. Ann Thorac Cardiovasc Surg, 2004, 10(2): 76-80.
29	Li S, Zheng Q, Ma Y, et al. Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of 18F-FDG PET/CT[J]. PLoS ONE, 2013, 8(10): e78552.
30	Gong X, Li X, Jiang T, et al. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer[J]. J Thorac Oncol, 2017, 12(7): 1085-109.

临床资料		转移(n＝36)	非转移(n＝56)	HR(95%CI)	P值
年龄(岁)		56.85±12．73	55.58±10．31	1.007(0.977～1.038)	0.657
性别构成(男/女)		17/21	24/22	1.116(0.603～2.232)	0.657
BMI(kg/m²)		20.81±2．41	21.49±1．92	0.899(0.796～1.052)	0.185
HIF-1α
	低表达	11	54	10.324(4.985～21.380)	<0.001
	高表达	25	2
PD-L1
	低表达	13	51	6.896(3.449～13.789)	<0.001
	高表达	23	5
TMN分期
	Ⅰ	9	32	2.952(1.387～6.285)	0.005
	Ⅱ	27	24
病理分型
	腺癌	24	41	1.188(0.594～2.377)	0.626
	非腺癌	12	15
CEA(ng/ml)		159.84±19．93	141.83±20．29	1.028(1.013～1.043)	<0.001
肿瘤直径(cm)		3.68±1．12	2.68±1．10	1.712(1.286～2.279)	<0.001
影像学特征
	毛刺征	14	21	1.094(0.559～2.138)	0.793
	血管集束征	6	14	0.715(0.298～1.719)	0.454
	胸膜凹陷	10	19	1.527(0.736～3.168)	0.255
	空洞	7	19	0.532(0.233～1.216)	0.135
	支气管血管束增厚	4	10	1.098(0.481～2.507)	0.824
病灶位置(左右肺)
	左肺	21	33	0.995(0.513～1.930)	0.995
	右肺	15	23
病灶分叶
	上叶	19	31	0.953(0.495～1.834)	0.885
	中、下叶	17	25

临床资料		转移(n＝36)	非转移(n＝56)	HR(95%CI)	P值
年龄(岁)		56.85±12．73	55.58±10．31	1.007(0.977～1.038)	0.657
性别构成(男/女)		17/21	24/22	1.116(0.603～2.232)	0.657
BMI(kg/m²)		20.81±2．41	21.49±1．92	0.899(0.796～1.052)	0.185
HIF-1α
	低表达	11	54	10.324(4.985～21.380)	<0.001
	高表达	25	2
PD-L1
	低表达	13	51	6.896(3.449～13.789)	<0.001
	高表达	23	5
TMN分期
	Ⅰ	9	32	2.952(1.387～6.285)	0.005
	Ⅱ	27	24
病理分型
	腺癌	24	41	1.188(0.594～2.377)	0.626
	非腺癌	12	15
CEA(ng/ml)		159.84±19．93	141.83±20．29	1.028(1.013～1.043)	<0.001
肿瘤直径(cm)		3.68±1．12	2.68±1．10	1.712(1.286～2.279)	<0.001
影像学特征
	毛刺征	14	21	1.094(0.559～2.138)	0.793
	血管集束征	6	14	0.715(0.298～1.719)	0.454
	胸膜凹陷	10	19	1.527(0.736～3.168)	0.255
	空洞	7	19	0.532(0.233～1.216)	0.135
	支气管血管束增厚	4	10	1.098(0.481～2.507)	0.824
病灶位置(左右肺)
	左肺	21	33	0.995(0.513～1.930)	0.995
	右肺	15	23
病灶分叶
	上叶	19	31	0.953(0.495～1.834)	0.885
	中、下叶	17	25

因　素	β	标准误	Wald	P值	HR	95%CI
因　素	β	标准误	Wald	P值	HR	LL	UL
HIF-1α高表达	3.25	1.021	10.138	0.001	25.790	10.005	30.287
PD-L1高表达	2.815	0.909	9.599	0.002	16.693	12.014	20.356
CEA	0.057	0.022	6.42	0.011	1.058	1.013	1.106

因　素	β	标准误	Wald	P值	HR	95%CI
因　素	β	标准误	Wald	P值	HR	LL	UL
HIF-1α高表达	3.25	1.021	10.138	0.001	25.790	10.005	30.287
PD-L1高表达	2.815	0.909	9.599	0.002	16.693	12.014	20.356
CEA	0.057	0.022	6.42	0.011	1.058	1.013	1.106

[1]	Guo Sun, Yingdong Xie, Chaoli Xu, Bin Yang. Clinical value of a nomogram based on ultrasonic and clinical features for predicting central and lateral cervical lymph node metastases of thyroid papillary carcinoma [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(07): 734-742.
[2]	Qiyang Chen, Yujiang Liu, Jinping Liu, Xiaoqu Tan, Linxue Qian, Xiangdong Hu. Diagnostic value of a predictive model based on contrast-enhanced ultrasound for prediction of central cervical lymph node metastasis in patients with thyroid papillary carcinoma [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(04): 442-448.
[3]	Sujuan Li, Wenbo Ding, Xinping Wu, Xuedong Deng. Ultrasound-related risk factors for cervical lymph node metastasis of papillary thyroid microcarcinoma with extracapsular invasion [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(04): 455-461.
[4]	Tingting Cui, Yanyu Li, Qian Wang, Xiaofeng Fu, Gonglin Fan, Li Gao, Lei Xie, Deguang Zhang, Jiang Zhu. Thyroglobulin assessment in needle washout after fine needle aspiration for diagnosis of cervical lymph metastasis of thyroid papillary carcinoma: threshold and efficacy [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(02): 219-226.
[5]	Xingchen Liu, Juan Liu, Baobao Wei, Jie Liu, Hui Liu. Correlation analysis of abnormal expression of XIAP and XAF1 with ovarian cancer [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 419-427.
[6]	Yong Li, Yong Quan, Shiyan Fu, Xinze Ran, Hong Tang, Suiyi Liu, Jie Li, Chang Shu, Yonglai Chen, Jing Zhang, Bingbing Yang, Yuhui Hao. Influence of hypoxia on acute radiation injuries in mice [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(04): 299-305.
[7]	Yong Quan, Xinze Ran, Mengjia Hu, Fang Chen, Naicheng Chen, Weinian Liao, Mo Chen, Mingqiang Shen, Shilei Chen, Song Wang, Junping Wang. Observation of effect on hypoxia acclimatization in repair of hematopoietic stem cells after acute radiation injury in mice [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(04): 293-298.
[8]	Yijun Fan, Feng Yang, Wei Wang, Heying Yin, Jun Liu. Research progress in the diagnostic and therapeutic value of Delphian lymph node metastasis in papillary thyroid carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 306-310.
[9]	Yonghao Li, Xuefei Gao, Tiantian Guo, Jin Zhang, Jing Liu. Current status of surgical approaches for papillary thyroid carcinoma of the isthmus [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(03): 225-230.
[10]	Cheng Xu, Lulu Wang, Shaohua Wang. Application of eluent thyroglobulin in metastatic lymph nodes of thyroid papillary carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 701-704.
[11]	Yutao Yuan, Jinlin Xing, Kefei Xie, Kai Yin. Correlation between CT findings and BRAF^V600E gene mutation and central lymph node metastasis in papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 611-614.
[12]	Xingli Shan, Dong Wang, Nianzeng Xing, Zejun Xiao, Yajian Li. Diagnostic value of ⁶⁸Ga-PSMA-PET /CT in pelvic lymph node metastasis of prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(03): 214-218.
[13]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[14]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[15]	Yuting Chen, Ying Zhou, Yafei Lu, Bin Jiang. Advances in the function and mechanism of hypoxic preconditioned mesenchymal stem cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(02): 115-120.

Please choose a citation manager

Content to export